Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
About this episode
The episode discusses Vertex Pharmaceuticals' recent acquisition of Crinetics, the rise in IPOs and venture capital for derisked companies, and the FDA's ongoing decision-making process amidst leadership challenges.
A surprising deal from Vertex Pharmaceuticals adds to Big Pharma’s acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.
Topics covered
- M&A activity
- IPO trends
- venture capital
- FDA decisions
- pharmaceutical industry
Keywords
- Vertex Pharmaceuticals
- Crinetics
- IPO
- venture capital
- FDA
- pharmaceuticals
- acquisition
Mentioned in this episode
Organizations: Vertex Pharmaceuticals, Crinetics, FDA
More episodes of BioSpace
- The future of pain relief: Exploring opioid alternatives
- Biogen validates anti-tau approach at AAIC, psychedelics full speed ahead, ATTR-CM shakeup
- Bonus: Q2 2026 Job Market Update
- From sequence to scale: Gene editing’s new era in biologics manufacturing
- Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
- The Golden Triangle and the gaps: Rethinking UK biotech
Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.